Julius Wolff Institute, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Research Centre, Shriners Hospital for Children-Canada, Department of Pediatric Surgery, McGill University, Montreal, Canada.
J Bone Miner Res. 2018 Sep;33(9):1686-1697. doi: 10.1002/jbmr.3454. Epub 2018 May 23.
During bone healing, tissue formation processes are governed by mechanical strain. Sost/sclerostin, a key Wnt signaling inhibitor and mechano-sensitive pathway, is downregulated in response to mechanical loading. Sclerostin neutralizing antibody (SclAb) increases bone formation. Nevertheless, it remains unclear whether sclerostin inhibition can rescue bone healing in situations of mechanical instability, which otherwise delay healing. We investigated SclAb's influence on tissue formation in a mouse femoral osteotomy, stabilized with rigid or semirigid external fixation. The different fixations allowed different magnitudes of interfragmentary movement during weight bearing, thereby influencing healing outcome. SclAb or vehicle (veh) was administeredand bone healing was assessed at multiple time points up to day 21 postoperatively by in vivo micro-computed tomography, histomorphometry, biomechanical testing, immunohistochemistry, and gene expression. Our results show that SclAb treatment caused a greater bone volume than veh. However, SclAb could not overcome the characteristic delayed healing of semirigid fixation. Indeed, semirigid fixation resulted in delayed healing with a prolonged endochondral ossification phase characterized by increased cartilage, lower bone volume fraction, and less bony bridging across the osteotomy gap than rigid fixation. In a control setting, SclAb negatively affected later stages of healing under rigid fixation, evidenced by the high degree of endosteal bridging at 21 days in the rigid-SclAb group compared with rigid-veh, indicating delayed fracture callus remodeling and bone marrow reconstitution. Under rigid fixation, Sost and sclerostin expression at the gene and protein level, respectively, were increased in SclAb compared with veh-treated bones, suggesting a negative feedback mechanism. Our results suggest that SclAb could be used to enhance overall bone mass but should be carefully considered in bone healing. SclAb may help to increase bone formation early in the healing process but not during advanced stages of fracture callus remodeling and not to overcome delayed healing in semirigid fixation. © 2018 American Society for Bone and Mineral Research.
在骨愈合过程中,组织形成过程受机械应变的控制。Sost/sclerostin 是 Wnt 信号抑制剂和机械敏感途径的关键调节因子,在机械加载时下调。Sclerostin 中和抗体(SclAb)增加骨形成。然而,目前尚不清楚在机械不稳定的情况下,抑制 Sclerostin 是否可以促进骨愈合,否则会延迟愈合。我们研究了 SclAb 在刚性或半刚性外固定稳定的小鼠股骨截骨模型中对组织形成的影响。不同的固定方式允许在负重时发生不同程度的断端间运动,从而影响愈合结果。在术后第 0、7、14 和 21 天,通过体内 micro-CT、组织形态计量学、生物力学测试、免疫组织化学和基因表达评估 SclAb 或载体(veh)给药对骨愈合的影响。结果表明,SclAb 治疗后骨体积大于 veh。然而,SclAb 不能克服半刚性固定的特征性延迟愈合。事实上,与刚性固定相比,半刚性固定导致愈合延迟,表现为软骨增加、骨体积分数降低、骨桥穿过截骨间隙减少的延长软骨内骨化阶段。在对照条件下,SclAb 在刚性固定下对后期愈合阶段产生负面影响,这表现在刚性-SclAb 组在第 21 天的骨干桥接程度较高,而刚性-veh 组则较低,表明骨折愈合延迟、骨痂重塑和骨髓重建。在刚性固定下,与 veh 处理的骨骼相比,SclAb 处理的骨骼中 Sost 和 Sclerostin 的基因和蛋白水平表达均增加,提示存在负反馈机制。我们的结果表明,SclAb 可用于增加总体骨量,但在骨愈合过程中应谨慎使用。SclAb 可能有助于在愈合过程的早期增加骨形成,但在骨折愈合的晚期阶段不能增加骨形成,也不能克服半刚性固定的延迟愈合。